[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550017":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":69,"collaborators":27,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":27,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":27,"enrollmentInfo":82,"targetDuration":27,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":62,"whyStopped":27,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Vinpocetine + Standard Therapy","EXPERIMENTAL","Vinpocetine capsules, 30 mg, twice daily, with meals for 3 months",[13,14],"Drug: Vinpocetine","Drug: Standard Therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo + Standard Therapy","PLACEBO_COMPARATOR","Placebo, twice daily, with meals for 3 months",[14,20],"Other: Placebo",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Vinpocetine","Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Standard Therapy","Anti-hypertensive and anti-diabetic medications according to the the institution's protocol",[16,9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Placebo","Starch-filled capsules, matching those of the intervention",[16],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Tamer El Said","CONTACT","201227366062","drtamer_elsaid@med.asu.edu.eg",[43,60],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Ain Shams University Hospital","NOT_YET_RECRUITING","Cairo","Abbasseia","11588","Egypt","EG",{"type":52,"coordinates":53},"Point",[54,55],31.24967,30.06263,{"lat":55,"lon":54},[58],{"name":38,"role":39,"phone":59,"phoneExt":27,"email":41},"01227366062",{"facility":61,"status":62,"city":46,"state":63,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Ain Shams Hospitals","RECRUITING","Abbasseya",{"type":52,"coordinates":65},[54,55],{"lat":55,"lon":54},[68],{"name":38,"role":39,"phone":59,"phoneExt":27,"email":27},{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Salma Hesham Bahram","Principal Investigator","100550017","phase-2-clinical-outcome-of-vinpocetine-in-diabetic-nephropathy-100550017",false,"NCT06441591","Clinical Outcome of Vinpocetine in Diabetic Nephropathy","The Effect of Vinpocetine on the Clinical Outcome of Patients With Diabetic Nephropathy","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml\u002Fmin) or stage 4 (eGFR 15-29 ml\u002Fmin),\n* Albumin\u002FCreatinine ratio (ACR): 30 - 300 μg \u002Fmg (microalbuminuria),\n* Stable standard therapy for at least three months prior to inclusion in the study.\n\nExclusion Criteria:\n\n* Kidney donor or recipient,\n* Active malignancy,\n* Pregnancy or breastfeeding,\n* Known intolerance or hypersensitivity to VPN,\n* Participation in other interventional trials,\n* Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits),\n* Patients with severe comorbidities\n* Patients receiving warfarin","ALL","18 Years",{"count":83,"type":84},64,"ESTIMATED","INTERVENTIONAL",[87,88],"PHASE2","PHASE3","The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients.\n\nThe following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life.\n\nParticipants will receive either vinpocetine or placebo, twice daily for 3 months.",[91,92],"Diabetic Kidney Disease","Diabetic Nephropathies",[24,94,95,96,97],"Diabetic nephropathy","diabetic kidney disease","UACR","ICAM","2024-07-10",{"date":100,"type":101},"2024-07-11","ACTUAL",{"date":98,"type":101},{"date":104,"type":84},"2025-06-01",{"name":5,"class":6},2]